Decreased Lung Function in Female but not Male Subjects With Established Cystic Fibrosis-Related Diabetes

Erika J. Sims, PhD
Michael W. Green, PhD
Anil Mehta, FRCP

OBJECTIVE — Although cystic fibrosis–related diabetes (CFRD) is associated with decreased lung function, sex is not known to influence CFRD. However, compared with male subjects with cystic fibrosis, female subjects with cystic fibrosis have increased morbidity. This study examines the association between female subjects with CFRD and poor lung function relative to male subjects using the percent predicted forced expiratory volume in 1 s (FEV₁) as a surrogate measure of morbidity.

RESEARCH DESIGN AND METHODS — We compared 323 patients with established CFRD with 489 cystic fibrosis control subjects with normal glucose tolerance (NGT) listed in the U.K. Cystic Fibrosis Database. Patients stratified by sex and chronic Pseudomonas aeruginosa infection were compared using binary logistic regression, and patients with new CFRD diagnoses were compared prospectively for the year 2002.

RESULTS — CFRD in female subjects (but not male subjects) without chronic P. aeruginosa infection had a 20% lower percent predicted FEV₁ compared with control subjects with NGT (95% CI −11.7 to −27.7; P < 0.0001). Genotype, age, treatment center, age at diagnosis of cystic fibrosis, pregnancy, liver function, or dose of pancreatic enzyme replacement therapy did not confound this female disadvantage. Comparison of female subjects with newly diagnosed CFRD free of chronic P. aeruginosa infection with matched control subjects with NGT showed no FEV₁ disadvantage in the 1st year after CFRD diagnosis.

CONCLUSIONS — Only female subjects with CFRD have significantly decreased lung function compared with sex-matched NGT control subjects. The absence of poor lung function in the first 12 months after diagnosis of diabetes suggests that an opportunity may exist to intervene and possibly prevent a decline in lung function, which can be as much as 20% in female subjects with CFRD.

Diabetes Care 28:1581–1587, 2005

Cystic fibrosis is the most common lethal autosomal recessive disease in whites, affecting ~1 in 2,500 births (1). Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (2). Cystic fibrosis–related diabetes (CFRD) occurs in 30–40% of adults and is associated with increased morbidity and mortality (3), accelerated decline in lung function, decreased BMI (4,5), and increased likelihood of infection with Pseudomonas species (5).

Female cystic fibrosis patients without CFRD have decreased lung function, earlier acquisition of chronic mucoid Pseudomonas aeruginosa infection (6), reduced survival (7), increased risk of premature death (7), reduced energy intake (8), and higher resting energy requirements (9) than their male counterparts. The excess female mortality produces a rising male-to-female ratio of 1.6:1 in patients aged >35 years in the U.K. (10). This prompted a study of CFRD to test the association between CFRD and cystic fibrosis morbidity in female subjects, using the validated measure of future mortality, forced expiratory volume in 1 s (FEV₁) (11). To overcome the potentially confounding effect of chronic P. aeruginosa infection (12), we stratified our cystic fibrosis patients by chronic P. aeruginosa status. We show that established CFRD is associated with a significant decline in lung function in female but not male subjects. However, a window of opportunity for intervention may exist that could improve the female outcome.

RESEARCH DESIGN AND METHODS — Patient data were obtained from the U.K. Cystic Fibrosis Database (UKCFD). Data for 2000–2002 were submitted by 41 specialist cystic fibrosis centers and 12 smaller cystic fibrosis clinics as recently described (13). Patients were eligible for inclusion if, in addition to biographical data, annual clinical data were available in both 2001 and 2002. Full details of data validation have
been described elsewhere (10,13). All procedures were compliant with multicenter research ethics protocols and U.K. legislation on patient confidentiality (13). Because multiple data were available for height, weight, and FEV1 per 12-month period, the means were used. *P. aeruginosa* and/or *Staphylococcus aureus* data were defined as intermittent if cultured on 1–2 occasions, or chronic if cultured on ≥3 occasions per 12-month period. Data for other organisms were analyzed as “ever cultured” per 12 months.

Patients receiving oral corticosteroids and transplant recipients were excluded (Fig. 1). The remaining patients were grouped by glucose tolerance test (GTT) result: 1) diabetic (including patients previously known to be diabetic), 2) equivocal (not shown), and 3) normal glucose tolerance (NGT). Patients who had not had a GTT performed in 2001 were designated as “not tested.” The categories of “not tested” and “equivocal” were excluded from the analyses. Potential bias may have been introduced by these exclusions. However, no differences were found in the percent predicted FEV1 between NGT and “not tested” male subjects with chronic *P. aeruginosa* infection (−1.0% [95% CI −5.7 to 3.7]) or NGT and “not tested” female subjects irrespective of chronic *P. aeruginosa* infection (without chronic *P. aeruginosa* infection −4.1% [−9.2 to 0.9]; with chronic *P. aeruginosa* infection −2.1% [−7.0 to 2.7]). NGT male subjects without chronic *P. aeruginosa* infection had lower percent predicted FEV1 compared with “not tested” males without chronic *P. aeruginosa* infection (−8.6% [−3.9 to −13.3]; *P* < 0.001) (see CONCLUSIONS).

Cross-sectionally, we compared patients aged ≥10 years who had CFRD in 2001 with NGT control subjects because the incidence of CFRD rises in the second decade of life. Patients were stratified into four populations according to sex and chronic *P. aeruginosa* status (Fig. 1). Using binary logistic regression (BLR), we compared CFRD and NGT patients within each stratified population. The model included the following covariates: percent predicted FEV1 (or percent predicted forced vital capacity [FVC] where indicated), age in 2001, age at cystic fibrosis diagnosis, pancreatic enzyme replacement dose (lipase · kg⁻¹ · day⁻¹), and height and weight Z scores. The following cofactors were also included in the model: diagnosis by neonatal screening, presence of intermittent *P. aeruginosa* infection, presence of liver dysfunction, pregnancy, and prescription of nutritional supplements. Because genotype influences survival (10), a subgroup analysis of the ΔF508/ΔF508 patients within each stratified population was performed. To determine the influence of the center’s policy,
we compared age (±3 years), sex, and center-matched NGT control subjects to CFRD patients. As there is a cohort effect in cystic fibrosis survival (14) and the prevalence of CFRD increases with age (15), we divided the stratified populations into 10-year age-groups. To validate our results, we repeated the BLR using data from all final study cohorts (a total of 812 study patients as defined in Fig. 1), modeling sex, chronic P. aeruginosa, and covariables that significantly differentiated CFRD and NGT patients in the four stratified populations. We tested for significant interactions between sex with chronic P. aeruginosa, sex with covariables, and chronic P. aeruginosa with covariables. Because of the small number of patients per center, it was not possible to include treatment center in this model.

Prospectively, we determined whether differences identified between the established CFRD and NGT populations were present in patients with newly diagnosed CFRD in 2002. After excluding transplant recipients and those receiving oral steroids, we identified 21 female and 25 male transplant recipients and those receiving chronic oral steroids. We identified 239 female (20%) and 209 male (15%) subjects with CFRD. Female subjects formed a significantly higher proportion of the CFRD subpopulation (53%; P = 0.007) despite a lower percentage (46% female) in the parent (2,640) population. The same sex difference was found in all mixed genotype subpopulations and also in the ∆F508/∆F508 parent and associated subpopulations. Additionally, in the parent and all subpopulations, ∆F508/∆F508 CFRD females formed a significantly higher proportion of the total ∆F508/∆F508 female population compared with equivalent ∆F508/∆F508 male populations (i.e., in the parent population: 146/641 female [23%] vs. 123/742 male [17%]) subjects.

In the absence of chronic P. aeruginosa, male and female subjects manifested different discriminatory elements between the CFRD and NGT subpopulations. For the 467 female and 581 male subjects (Fig. 1), 52 CFRD female subjects were discriminated from 93 NGT females only by a significantly lower percent predicted FEV₁ (−20.0%, [95% CI −11.75 to −27.68]; P < 0.0001) (Fig. 2A). In contrast, although the percent predicted FEV₁ was nondiscriminatory (2.38, [−6.38 to 11.26]; NS) (Fig. 2A), 44 CFRD male subjects were discriminated from 110 NGT males by an older age in 2001 (7.0 years [10.0–4.0]; P < 0.0001) and an earlier age at cystic fibrosis diagnosis (−6 months [0 to −10.0]; P < 0.001), no difference was found when the subpopulations were compared directly (Table 1). Comparable results were obtained when FVC was substituted for FEV₁ (BLR data not shown; for direct comparisons see Table 1). Comparable discriminatory variables and significant differences on direct comparison (Table 1 and Fig. 2A) were also found when ∆F508/∆F508 CFRD female and male subjects were compared with genetically matched NGT control subjects. Additionally, when matched against NGT control subjects for age, sex, and clinic (Fig. 2A), female subjects also had significantly worse percent predicted FEV₁ (−16.1% [−28.35 to −0.79]; P < 0.05) than male subjects (9.1% [−4.69 to 23.82]; NS).

Chronic P. aeruginosa–infected CFRD females were discriminated by a lower percent predicted FEV₁ (−14.0% [95% CI 8.11–19.91]; P < 0.0001) (Fig. 2B) and an older age in 2001 (7.0 years [5.0–8.0]; P < 0.0001) than chronic P. aeruginosa–infected NGT control subjects. Chronic P. aeruginosa–infected CFRD males were also older in 2001 (5.0 years [4.0–7.0]; P < 0.0001) but were additionally shorter (−0.54 SD, [−0.15 to −0.66]; P = 0.0015) than chronic P. aeruginosa–infected NGT control subjects. For males, although the percent predicted FEV₁ was not discriminatory, direct comparison showed that chronic P. aeruginosa–infected CFRD males had a significantly lower percent predicted FEV₁ (−10.0% [−4.30 to −16.07]; P = 0.0006) (Fig. 2B and Table 1) compared with their chronic P. aeruginosa–infected NGT control subjects. Similar findings were observed in ∆F508/∆F508 chronic P. aeruginosa–infected populations (females −17.0% [−20.44 to −4.79]; P = 0.002 and males −10.8% [−19.95 to −5.00]; P = 0.001) (Fig. 2B). On comparison of chronic P. aeruginosa–infected CFRD patients to age-, sex-, and center-matched control subjects, CFRD female but not male subjects still had significantly lower percent predicted FEV₁ compared with matched NGT control subjects (females −9.35% [−16.41 to −0.96]; P < 0.05 and males −3.39% [−8.74 to 2.70]; NS) (Fig. 2B).

When the BLR analysis was repeated using the final study cohort of 812 patients (Fig. 1), female subjects had a greater likelihood of having CFRD than male subjects (odds ratio [OR] 12.38 [95% CI 2.6–59.0]; P = 0.002). CFRD patients, irrespective of sex or P. aeruginosa status, were discriminated by a lower percent predicted FEV₁ (0.94 [0.91–0.97]; P < 0.001), height Z score (0.74 [0.57–0.95]; P = 0.017) and older age in 2001 (1.07 [1.01–1.14]; P = 0.022) from NGT control subjects. Of the interactions studied, a significant interaction was observed only between percent predicted FEV₁ and sex (1.02 [1.01–1.04]; P = 0.003), whereby CFRD female subjects were more likely than CFRD male subjects to be associated with a lower percent predicted FEV₁ compared with NGT control subjects.

CFRD male and female subjects were significantly older than sex-matched NGT control subjects (Table 1). However, when stratified into three 10-year age-groups, CFRD females without chronic P. aeruginosa infection (but not males) retained significantly lower percent predicted FEV₁ compared with NGT control subjects (Table 2) in all age-groups. For chronic P. aeruginosa–infected popula-
tions, only CFRD male and female sub-
jects aged 10–19 years had significantly
lower percent predicted FEV1 compared
with matched NGT control subjects (Ta-
ble 2). No other significant confounders
due to infection were present (Table 2).

To determine whether females with
CFRD had a diminished percent pre-
dicted FEV1 before diagnosis, we identi-
fied cohorts of females and males free
from chronic P. aeruginosa and without
CFRD at the time of annual review in
2001 in whom CFRD was subsequently
diagnosed by the time of annual review in
2002 and matched these to NGT control
subjects. Males with newly diagnosed
CFRD but nonequivalent females had sig-
nificantly lower percent predicted FEV1
compared with NGT control subjects
(male subjects −15.7% [95% CI −24.9
to −5.8; P = 0.003; females 1.7% [−8.95
to 11.64]; NS). This suggests that the de-
cline in percent predicted FEV1 in female
but not in male subjects occurs after 1 year
of CFRD (see Fig. 3 in the online appen-
dix at http://care.diabetesjournals.org).

**CONCLUSIONS**—CFRD adds an
additional burden of care for cystic fibro-
sis patients already taking many drugs to
maintain lung function. We find that fe-
nale but not male subjects with estab-
lished CFRD but without chronic P. aeruginosa
infection had 20% worse per-
cent predicted FEV1 compared with
matched NGT control subjects. These results
could not be explained by genotype, local cystic
fibrosis center policies, age, or chronic S.
aureus infection. This suggests that the
combination of CFRD and female sex
might have an adverse impact on survival
because a low percent predicted FEV1 is
predictive of premature mortality (17).

These results are in agreement with sur-
vival data recently reported by Moran
(18), who showed that females with cystic
fibrosis and CFRD had a reduced survival
by at least 17 years (median survival 30.7
years) compared with females with cystic
fibrosis without CFRD (47.0 years) or
males with cystic fibrosis irrespective of
CFRD (47.4 with CFRD and 49.5 years
without CFRD). We also report that al-
though CFRD has greater morbidity in fe-
nales, the onset of this adverse outcome
is not present within 12 months of the
initial diagnosis. Although caution must

---

**Figure 2**—Adverse impact of CFRD on female predicted FEV1 percentage when stratified by chronic P. aeruginosa (PA) infection. A: Chronic P. aeruginosa–free females and males. B: Chronic P. aeruginosa–present females and males. Box plots in the left and middle panels show median FEV1 in female and male subjects with CFRD (□) compared with control subjects with NGT (□). 95% CIs are also indicated (●). Left panels show all patients, middle panels show ΔF508/ΔF508 patients, and right panels show FEV1, for age-, sex-, and center-matched CFRD and NGT patients. Median FEV1 is indicated by black bar. The number of patients in each group is shown on the abscissa.
be exercised given the small numbers in our final study cohorts, we believe that this is a potentially important observation because it could provide a therapeutic window in which to test strategies to attenuate a long-term decrease in female lung function. Further, our data suggest that CFRD males may have a transient decrease of FEV$_1$ percentage immediately after CFRD diagnosis.

Many studies report that CFRD induces decreased lung function compared with that in NGT control subjects (19), but they do not separate their study populations by chronic $P. aeruginosa$ infection and sex. Koch et al. (19) compared patients with and without $P. aeruginosa$, where infection was defined as the presence of at least one positive culture in a 12-month period and found that infected CFRD patients had significantly lower percent predicted FEV$_1$ compared with infected non-CFRD patients, irrespective of sex. However, for non-infected groups they did not distinguish between the transient or chronic nature of the infection. When we reanalyzed our data using the infection model reported by Koch et al. (19), both CFRD female and male subjects with $P. aeruginosa$ had significantly lower FEV$_1$ than NGT control subjects, thus masking our reported sex effect (data not shown).

Why do females with established CFRD have worse lung function than males?

Mismatched energy consumption and expenditure? Recently, Collins et al. (8) showed that females with cystic fibrosis have a significantly lower energy intake, possibly contributing to their reduced survival. These data were not collected in the UKCFD but the UK male-to-female ratio increases with age (10). Allen et al. (9) reported that females with cystic fibrosis have increased resting energy expenditure compared with healthy females irrespective of cystic fibrosis and sex. However, neither study separated their populations by CFRD status, which might be relevant because CFRD disturbs lipid metabolism. Hardin et al. (20) reported that de novo lipogenesis, an energy-wasteful state, associates with both glucose intolerance and CFRD but not NGT. Fatty acid metabolism and lung function are intimately linked (21), and the combination of these factors could account for reduced pulmonary function (and earlier death) in females with established CFRD.

### Table 1—Patient Characteristics

|                  | No chronic $P. aeruginosa$ infection | Chronic $P. aeruginosa$ infection | No chronic $P. aeruginosa$ infection | Chronic $P. aeruginosa$ infection |
|------------------|-------------------------------------|----------------------------------|-------------------------------------|----------------------------------|
|                  | CFRD                                | NGT                              | Male subjects                       | Female subjects                  |
|                  |                                      |                                  |                                     |                                   |
| Median age (years) | 25.5 (27.5)                         | 18.0* (17.0)†                    | 24.5 (26.0)                         | 18.0* (17.0)†                    |
| Median age at diagnosis (months) | 4.0 (4.0) | 6.0 (6.0)†             | 12.0 (15.0)                        | 6.0 (6.0)†             |
| Median % predicted FEV$_1$ | 71.4 (73.3) | 73.6* (75.4)† | 53.6 (57.5) | 49.0 (49.0) |
| Median height Z score | 0.91 (0.83) | 0.78 (0.63) | 1.10 (1.00) | 0.46 (0.36)† |
| Median weight Z score | 0.78 (0.62) | 0.53 (0.30) | 0.82 (0.94) | 0.16 (0.06) |
| Median BMI (kg/m$^2$) | 21.8* (21.9) | 20.0 (20.5) | 20.1 (20.2) | 20.5 (20.5) |
| Median lipase dose (units/kg/day) | 7002 (4495) | 6342 (4987) | 4939 (3933) | 5725 (5111) |
| Percent receiving CFRD medication | 91 (96) | 86 (88) | 93 (98) | 92 (91) |

Data shown are for all genotypes (homozygous *F508*). *P* $< 0.05$ between CFRD male and female subjects vs. their sex-matched NGT control subjects. †*P* $< 0.05$ between homozygous *F508* CFRD male and female subjects vs. their genotype- and sex-matched NGT control subjects.
CFRD females. Indeed, the dose of pancreatic enzyme replacement therapy was higher in all CFRD populations (Table 1), consistent with increased energy demands, although we found no significant sex differences. Abnormal energy balance is likely to be exacerbated by chronic *P. aeruginosa* infection (22), which further increases resting energy expenditure. This could partially explain why the magnitude of the difference in lung function is greater in chronic *P. aeruginosa* infection (22), which further increases resting energy expenditure.

This female disadvantage is only observed in the chronic *P. aeruginosa*–infected 10- to 19-year age-group, presumably because the longer-term destruction of the lung by chronic *P. aeruginosa* infection is a sex-independent effect. Our data on the absence of a short-term effect of CFRD on female (but not male) lung function suggests a detrimental impact of CFRD >12 months after the CFRD diagnosis. Prospective studies providing a detailed comparison of clinical data for CFRD and NGT males and females are required to validate both of our hypotheses.

**Psychological or adherence factors?**

Adherence to treatment in chronic disease is important for outcome. The impact of a diagnosis of CFRD on quality of life in cystic fibrosis is unknown. However, because it is often perceived as an end-stage complication by many patients (23), CFRD may introduce a philosophy of negativity and poor concordance. This might be worse in female subjects, given the greater likelihood of nonadherence (24) and overestimation of weight (25) compared with males. Indeed, irrespective of chronic *P. aeruginosa* infection, CFRD female but not male subjects had significantly lower weight Z scores compared with NGT control subjects. As the prevalence of eating disorders within the cystic fibrosis population or CFRD subpopulation is poorly understood, the relative contributions of the additional impact of CFRD and an eating disorder per se are unknown. The need to comply with peer pressure and the media’s perception of the ideal body weight, particularly in females, may undermine optimum treatment regimens and contribute to poor outcome.

**Study limitations**

The cross-sectional nature of our analysis could have introduced selection bias, although comparison of our population profile with that of previously published studies (6,19,26,27) suggests otherwise. The higher proportion of female than male subjects with CFRD was consistent with previously published data by Yung and Hodson (27), and the higher proportion of female than male subjects with CFRD and chronic *P. aeruginosa* was also consistent with those of Demko et al. (6). The shorter stature of our CFRD population compared with NGT control subjects was in agreement with data of Ripa et al. (26). Furthermore, other factors such as pregnancy, liver dysfunction, and nutritional support were too infrequent to account for our results in women. The paucity of pregnancies in our dataset is discussed elsewhere (28).

Debate surrounds the treatment of patients with CFRD who do not have fasting hyperglycemia. Unlike those in the U.S. (29), U.K. guidelines for the treatment of CFRD advocate the initiation of insulin irrespective of fasting hyperglycemia for most patients with CFRD (30). Because the UKCFD does not collect data on fasting hyperglycemia status, it was not possible to study such patients in our analysis. We did identify a small percentage of patients who were not receiving CFRD medication (Table 1). Exclusion of these patients did not affect our results (data not shown).

Because not all patients in 2001–2002 had a GTT performed, selection bias remains an issue. NGT males without chronic *P. aeruginosa* infection but not equivalent NGT females had significantly lower percent predicted FEV₁ compared with respective “equivalent” and “not tested” patients. One possibility is that males with a decrease in FEV₁ are preferentially screened for CFRD. Although significantly more male (390) than female (313) subjects underwent a GTT, the number tested was in proportion to the number of male and female subjects in each eligible population (1,073 and 836, respectively). We have recently shown that, although GTTs are advocated in the U.K. for all cystic fibrosis patients aged >12 years (31), <50% were actually performed. This was unrelated to staffing provision (32), suggesting differences in center protocols as a primary driving force. Nevertheless, we do not believe that significant bias is introduced because our adverse findings in CFRD females were also confirmed when center-matched patients and control subjects were studied, suggesting that the frequency of testing within centers was an unlikely confounder. One conclusion from our study is that measures to increase the prevalence of screening for CFRD are needed.

In summary, we describe sex as an important factor in the relationship between CFRD and lung function. This was not confounded by lung infection. In CFRD females, but not CFRD males, we report 14–20% lower percent predicted FEV₁ and FVC, irrespective of chronic *P. aeruginosa* infection, compared with NGT control subjects that are unexplained by genotype, center effects, or age. The absence of poor lung function in the first 12 months after diagnosis of diabetes in females suggests that an opportunity may exist to intervene and possibly prevent a longer-term decline in lung function, as much as 20% in females with CFRD. The

---

**Table 2—Difference in median FEV₁ percentages in CFRD patients compared with age- and sex-matched control subjects**

| Age-group          | No chronic *P. aeruginosa* infection | Chronic *P. aeruginosa* infection |
|--------------------|-------------------------------------|----------------------------------|
|                    | Females                             | Males                            | Females                        |
| 10–19 years        | −12.6 (−0.72 to −26.12)             | −1.1 (14.10 to −17.83)†          | −17.4 (−5.45 to −29.86)‡        |
| 20–29 years        | −15.4 (−3.53 to −29.40)             | 3.0 (21.23 to −12.75)†           | −3.4 (5.11 to −11.95)‡          |
| ≥30 years          | −15.1 (−2.76 to −31.81)             | 6.0 (24.23 to −13.45)†           | −6.9 (6.68 to −15.96)†          |

Data are medians (95% CI). *P < 0.05; † NS.
extent to which this will materially affect the final outcome remains to be established. We recommend a study to evaluate treatment intensity in females with cystic fibrosis and newly diagnosed CFRD, using lung function as a primary outcome.

Acknowledgments — This work was funded by the Cystic Fibrosis Trust and the National Services Division of NHS (Scotland).

We thank G. Mehta for coordinating the database, M. Fraser and S. Krawczyk for their expert data validation, and Dr. Allan Clark (UEA) for additional statistical advice. We also thank the directors and data managers at specialist cystic fibrosis centers and cystic fibrosis clinics throughout the U.K. for contributing data to the U.K. Cystic Fibrosis Database.

References
1. Davis PB, Drumm M, Konstam MW: Cystic fibrosis. Am J Respir Crit Care Med 154: 1229–1256, 1996
2. Population variation of common cystic fibrosis mutations. The Cystic Fibrosis Genetic Analysis Consortium. Hum Mutat 4:167–177, 1994
3. Finkelstein SM, Wielinski CL, Elliott GR, Warwick WJ, Barbosa J, Wust C, Klein DJ: Diabetes mellitus associated with cystic fibrosis. J Pediatr 112:373–377, 1988
4. Lanns S, Thorsteinsson B, Nerup J, Koch C: Diabetes mellitus in cystic fibrosis: effects of insulin therapy on lung function and infections. Acta Padiatr 83:849–853, 1994
5. Milla CE, Warwick WJ, Moran A: Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 162:891–895, 2000
6. Demko CA, Byard PJ, Davis PB: Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 48: 1041–1049, 1995
7. Aurora P, Wade A, Whitmore P, Whitehead B: A model for predicting life expectancy of children with cystic fibrosis. Eur Respir J 16:1056–1060, 2000
8. Collins CE, O’Loughlin EV, Henry R: Discrepancies between males and females with cystic fibrosis in dietary intake and pancreatic enzyme use. J Pediatr Gastroenterol Nutr 26:258–262, 1998
9. Allen JR, McCauley JC, Selby AM, Waters DL, Gruca MA, Baur LA, Van Asperen P, Gaskin KJ: Differences in resting energy expenditure between male and female children with cystic fibrosis. J Pediatr 142: 15–19, 2003
10. McCormick J, Green MW, Mehta G, Culross F, Mehta A: Demographics of the UK cystic fibrosis population: implications for neonatal screening. Eur J Hum Genet 10: 583–590, 2002
11. Haylar KM, Williams SG, Wise AE, Pouria S, Lombard M, Hodson ME, Westaby D: A prognostic model for the prediction of survival in cystic fibrosis. Thorax 52:313–317, 1997
12. Schaedel C, de Monestrol I, Hjelte L, Johannessson M, Kornfelt R, Lindblad A, Strandvik B, Wahlgren L, Holmberg L: Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 33: 483–491, 2002
13. Mehta G, Sims EJ, Culross F, McCormick J, Mehta A: Potential benefits of the UK Cystic Fibrosis Database. J R Soc Med 97: 60–71, 2004
14. Dodge JA, Morison S, Lewis PA, Coles EC, Geddes D, Russell G, Littlewood JM, Scott MT: Incidence, population, and survival of cystic fibrosis in the UK, 1968–95: UK Cystic Fibrosis Survey Management Committee. Arch Dis Child 77:493–496, 1997
15. Mackie ADR, Thornton SJ, Edenborough FP: Cystic fibrosis-related diabetes. Diabet Med 20:425–436, 2003
16. Bland M: An Introduction to Medical Statistics. Oxford, Oxford Medical Publications, 2000
17. Milla CE, Warwick WJ: Risk of death in cystic fibrosis patients with severely compromised lung function. Chest 113: 1230–1234, 1998
18. Moran A: CFRD: pathogenesis and prognosis. Pediatr Pulmonol 27:S13.1, 2004
19. Koch C, Rainisio M, Madessani U, Harms HK, Hodson ME, Mastella G, McKenzie SG, Navarro J, Strandvik B: Presence of cystic fibrosis-related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: data from the European Epidemiologic Registry of Cystic Fibrosis. Pediatr Pulmonol 32:343–350, 2001
20. Hardin DS, LeBlanc A, Para L, Seilheimer DK: Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis. Diabetes 48:1082–1087, 1999
21. Schoni MH, Casaulta-Aebischer C: Nutrition and lung function in cystic fibrosis patients: review. Clin Nutr 19:79–85, 2000
22. Vinton NE, Padman R, Davis M, Harcke HT: Effects of Pseudomonas colonization on body composition and resting energy expenditure in children with cystic fibrosis. J Parenter Enteral Nutr 23:233–236, 1999
23. Wilson DC, Kalmins D, Stewart C, Hamilton N, Hanna AK, Durie PR, Tullis E, Pencharz PB: Challenges in the dietary treatment of cystic fibrosis related diabetes mellitus. Clin Nutr 19:87–93, 2000
24. Czyzewski DI, Koocher G: Medical compliance and coping with cystic fibrosis. J Child Psychol Psychiatry 28:311–319, 1987
25. Walters S: Sex differences in weight perception and nutritional behavior in adults with cystic fibrosis. J Hum Nutr Diet 14: 83–91, 2001
26. Ripa P, Robertson I, Cowley D, Harris M, Masters IB, Cotterill AM: The relationship between insulin secretion, the insulin-like growth factor axis and growth in children with cystic fibrosis. Clin Endocrinol 56: 383–389, 2002
27. Yung B, Hodson ME: Diabetes in cystic fibrosis. J R Soc Med 92:35–340, 1999
28. Boyd JM, Mehta A, Murphy DJ: Fertility and pregnancy outcomes in men and women with cystic fibrosis in the United Kingdom. Hum Reprod 19:2238–2243, 2004
29. Moran A: Diagnosis, screening, and management of cystic fibrosis-related diabetes. Curr Diab Rep 2:111–115, 2002
30. Littlewood JM, Hilton D, Bridges N, Gyi K, Hodson ME, Jones K, McKenna D, Mortson A, Peckham D, Roberts J, Rowe R, Sheldon C, Verma A, Wyatt H: Management of cystic fibrosis related diabetes mellitus. Kent, U.K., Cystic Fibrosis Trust, 2004
31. Cystic Fibrosis Trust: Standards for the Clinical Care of Children and Adults with Cystic Fibrosis in the UK 2001. Kent, U.K., Cystic Fibrosis Trust, 2001
32. Sims EJ, McCormick J, Green MW, Mehta G, Culross F, Mehta A: Oral glucose tolerance testing for cystic fibrosis related diabetes-poor staffing alone cannot explain failure to meet the standards of care. J Cystic Fibrosis 2:383, 2003